Should EMS Leave Patients at Home After Successful Adenosine Cardioversion for Known SVT?
No, EMS should not routinely leave patients at home after adenosine cardioversion for SVT, but a carefully structured treat-and-release protocol can be safe for highly selected patients who meet strict criteria.
The Evidence for Treat-and-Release
The only published prehospital treat-and-release protocol for SVT demonstrated that this approach is viable for uncomplicated cases, with a 13% EMS re-presentation rate within 72 hours and only 5% requiring ED evaluation 1. However, all re-presentations in this study were attributed to a single individual, suggesting that patient selection is critical 1. The protocol applied to a significant proportion of SVT patients (approximately one-third of all cases), and paramedic adherence to strict criteria was 72% 1.
Critical Safety Concerns That Mandate Transport
Adenosine Can Precipitate Life-Threatening Arrhythmias
- Adenosine may precipitate atrial fibrillation with rapid ventricular response or even ventricular fibrillation, requiring immediate defibrillation 2, 3, 4.
- Fatal and nonfatal cardiac arrest, sustained ventricular tachycardia requiring resuscitation, and myocardial infarction have occurred following adenosine administration 4.
- Hemorrhagic and ischemic cerebrovascular accidents have been reported as complications of adenosine 4.
- New-onset or recurrent convulsive seizures, some prolonged and requiring emergent anticonvulsive management, have occurred after adenosine 4.
Post-Conversion Arrhythmias Are Common
- Patients often develop atrial or ventricular premature complexes immediately after conversion that may induce further episodes of SVT, potentially requiring antiarrhythmic drugs to prevent acute reinitiation 2, 3.
- Adenosine can cause atrial fibrillation in patients with or without prior history, typically beginning 1.5 to 3 minutes after initiation and lasting 15 seconds to 6 hours 4.
Diagnostic Accuracy Limitations
- Even in physician-staffed EMS systems with high diagnostic accuracy (90.7%), dangerous misdiagnoses such as ventricular tachycardia still occur in approximately 2% of cases 5.
- Paramedic accuracy in rhythm interpretation remains only fair to moderate (kappa 0.37-0.43), with studies showing that only 79-84% of cases treated as SVT were actually SVT 6, 7, 8.
When Treat-and-Release May Be Considered
If your EMS system implements a treat-and-release protocol, all of the following strict criteria must be met 1:
- Confirmed conversion to normal sinus rhythm documented on 12-lead ECG
- Hemodynamically stable throughout the entire encounter (no hypotension, altered mental status, chest pain, or heart failure symptoms)
- No recurrence of SVT during observation period
- Known history of SVT with prior similar episodes
- No high-risk features: no pre-excitation (WPW), no structural heart disease, no recent myocardial infarction
- Patient able to follow up with cardiology or primary care within 24-48 hours
- Patient understands warning signs and agrees to call 911 if symptoms recur
- No complications from adenosine administration (no prolonged chest pain, dyspnea, or neurologic symptoms)
The Default Recommendation: Transport to ED
The safest approach is to transport all patients after adenosine cardioversion for the following reasons:
Ongoing Risk Assessment
- The ACC/AHA/HRS guidelines do not address prehospital treat-and-release; all recommendations assume hospital-based care with continuous monitoring 2.
- Adenosine's hemodynamic effects including hypotension and hypertension can persist, with some cases of hypertension lasting several hours 4.
Need for Definitive Management
- Catheter ablation is recommended as first-line definitive therapy for recurrent symptomatic SVT, with single-procedure success rates of 94.3-98.5% 3, 9.
- Patients with recurrent SVT requiring prehospital intervention are ideal candidates for ablation referral, which requires ED evaluation and cardiology consultation 3, 9.
Medicolegal and Quality-of-Life Considerations
- Untreated recurrent PSVT is associated with high symptom burden and can lead to tachycardia-mediated cardiomyopathy in 1% of cases 9.
- Transport allows for comprehensive evaluation to exclude underlying structural heart disease, pre-excitation syndromes, and other conditions that increase risk 2.
Common Pitfalls to Avoid
- Never leave a patient at home if there is any uncertainty about rhythm diagnosis or if the patient had any hemodynamic instability at any point during the encounter 2.
- Do not assume successful cardioversion means the patient is safe to remain home—serious complications can occur after apparent successful treatment 4.
- Avoid treat-and-release in patients with first-time SVT—these patients require comprehensive evaluation to determine the mechanism and assess for underlying cardiac disease 3, 9.
- Never implement treat-and-release without a formal protocol that includes strict inclusion/exclusion criteria, mandatory observation periods, and quality assurance monitoring 1.
Algorithmic Approach to Decision-Making
Successful cardioversion achieved?
- No → Transport immediately
- Yes → Proceed to step 2
Any hemodynamic instability at any point? (hypotension, altered mental status, chest pain, heart failure symptoms)
- Yes → Transport immediately
- No → Proceed to step 3
Known history of SVT with prior similar episodes?
- No → Transport immediately (first episode requires full evaluation)
- Yes → Proceed to step 4
Any complications from adenosine? (prolonged chest pain, dyspnea, neurologic symptoms, recurrent arrhythmia)
- Yes → Transport immediately
- No → Proceed to step 5
Does your EMS system have an approved treat-and-release protocol with medical director oversight?
- No → Transport (treat-and-release requires formal protocol)
- Yes → May consider treat-and-release if patient meets ALL protocol criteria and has reliable follow-up arranged within 24-48 hours 1
In the absence of a formal, medically supervised treat-and-release protocol, the standard of care is to transport all patients after adenosine cardioversion for SVT.